You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Direct-read monitor for airborne viral pathogens

    SBC: AEROSOL DEVICES INC            Topic: NIAID

    Aerosolized pathogenssuch as Influenza virusescan spread rapidly and silently throughout a populationcausing severe outbreaks that can be difficult to controlEarly detection of these airborne pathogens is key to controlling outbreaksespecially among vulnerable populations such as in hospitalstreatment centers or nursing homesYet available methods are neither rapidnor portableCurrent methods rely h ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. A2A receptor blockade for sepsis

    SBC: Purine Pharmaceuticals Inc.            Topic: NIAID

    SUMMARY Sepsis is a clinical syndrome that complicates severe infectionSepsis remains the leading cause of morbidity and mortality in critically ill patientsThere are no specific FDA approved medicines for the treatment of sepsisCurrent concepts of the pathophysiology of sepsis suggest that organ failure and mortality in sepsis are caused by inappropriate regulation of the immune systemThis manife ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. An Advanced Lung Organomimetic to Reproduce Human Airway Pathophysiology

    SBC: PNEUMAX, LLC            Topic: 113

    PROJECT SUMMARYThree of top five causes of death in humans globally are lung relatedchronic obstructive pulmonary diseaseCOPDlower respiratory infections and lung cancers collectively account for over eight million deaths annuallyCurrentlyin preclinical settingstatic cell cultures and animal models are the most widely used systems for mechanistic and translational studiesHowevercritical limitation ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. microRNA-21 Blockade of Triple Negative Breast Cancer

    SBC: BOUND THERAPEUTICS LLC            Topic: 102

    Triple negative breast cancerTNBCis an orphan disease that attacksUS women every yearTNBC cells lack human estrogen receptorprogesterone receptorand epidermal growth factor receptorHerthe targets of existing medicinesTNBC recurs after standard of care chemotherapy and radiationkilling its victims withinyearsNew promising therapies such as poly ADP ribosepolymerasePARPinhibitors only benefit a smal ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. The Point Digit: A ratcheting prosthetic finger using advanced rapid manufacturing technology

    SBC: POINT DESIGNS, LLC            Topic: NICHD

    The Point DigitA Ratcheting Prosthetic Finger UsingAdvanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop and commercialize a purely mechanicalratcheting prosthetic fingerthe Point Digitwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s metacar ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. A Portable Device for Accurate Mouse Tail Vein Injection

    SBC: Technology Commercialization Partners LLC            Topic: OD

    PROJECT SUMMARYABSTRACT To datethe standard method to access a mouse tail vein is manual injectionbut its yield rate is poor in generalThis leads to multiple needle insertions associated with tissue damage and painBesidesfailure in tail vein injection leads to data lossand thereby more animals will be required to compensate itFinallythe dose variation induced by unreliable injection increases erro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: R41

    Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Integrated Microbial Screening and Antimicrobial Susceptibility Test on Microfluidic Digital Array for Diagnosis of Urinary Tract Infections

    SBC: Combinati Incorporated            Topic: NIAID

    Abstract COMBiNATi will work with Stanford University to bring the world s first integrated ID AST UTI diagnostic platform to the market by combining COMBiNATi sone clickcost effective dPCR platform with Stanford s pathogen identificationIDHRMA algorithm for broad detectiondeep characterization and absolute quantification of UTI pathogensBy the end of the Phaseprojectwe will deliver the prototype ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: CETYA THERAPEUTICS, INC.            Topic: NHLBI

    PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government